The purpose of this study is to determine whether raloxifene compared with placebo lowers the risk of coronary events and reduces the risk of invasive breast cancer in postmenopausal women at risk for major coronary events.
Postmenopausal women with established coronary heart disease or at risk for a major coronary event.
Exclusion Criteria:
Postmenopausal symptoms that required estrogen replacement therapy. Suspected or known history of breast or endometrial carcinoma. Known or probable history of deep venous thrombosis, pulmonary embolism, or retinal vein thrombosis. New York Heart Association classes III or IV heart failure.
Let’s see if you might be eligible for this study.
What is your age and gender ?
Submit
There is 1 Location for this study
See Locations Near You
For additonal information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician Minneapolis Minnesota, , United States
